FRAXA's Impact to Date

$
0
32,306,347

Direct Investment in Fragile X Research

0
6

ONGOING FRAGILE X CLINICAL TRIALS AND STUDIES

Current Clinical Trials
0
41

TEAMS ACTIVELY RESEARCHING FRAGILE X

Current Research Grants
0
4

GENE THERAPY AND PROTEIN REPLACEMENT STUDIES

Current Studies
0
31

PHARMACEUTICAL AND BIOMEDICAL PARTNERS

0
618

RESEARCH GRANTS AWARDED

0
19

COUNTRIES ARE HOME TO RESEARCH TEAMS

What is Fragile X Syndrome?

Fragile X syndrome (FXS) is the most common inherited cause of autism and intellectual disabilities. It affects 1 in 4,000 boys and 1 in 8,000 girls worldwide.

Fragile X syndrome occurs when a single gene on the X chromosome shuts down. This gene makes a protein needed for normal brain development. In FXS it does not work properly, the protein is not made, and the brain does not develop as it should.

Learn more about Fragile X syndrome

How Does FRAXA Help?

FRAXA’s mission is to find effective treatments and ultimately a cure for Fragile X syndrome. We directly fund research grants and fellowships at top universities around the world. We partner with biomedical and pharmaceutical companies, large and small, to bridge the gap between research discoveries and actual treatments.

Treatments for Fragile X are likely to help people affected by autism, Alzheimer’s, and other brain disorders.

Donate to FRAXA's mission

Latest Fragile X News & Updates

View all News & Updates

$100,000 Donor Matching Challenge From The Robert & Ardis James Foundation

We are thrilled to announce FRAXA Research Foundation’s most significant and unique matching challenge of the year, thanks to the Robert & Ardis James Foundation. This challenge will help us bring top new talent to Fragile X research.
Read more

16th Annual Fragile X Poker Run Raises nearly $29,000

The 16th Annual Fragile X Poker Run took place July 31 - August 2, 2021 in North Carolina. The generosity of the participants raised nearly $29,000 for FRAXA and Fragile X Research! Great family and friends from 10 different states attended the event, one friend even came from Israel!
Read more

Characterization of a Novel CYFIP1 – Derived Peptidomimetic Restoring the Dysregulated mRNAs Translation: Toward An Innovative Therapeutic Strategy for FXS

The researchers are developing next-generation drugs called peptidomimetics, using the functional features of FMRP. If they succeed, the hope is that we will have new drugs that could make up for the loss of FMRP, thus treating Fragile X syndrome.
Read more

Bruins 50/50 Benefits Fragile X Research

As the Bruins took to the ice to score a big win over the Detroit Red Wings, FRAXA volunteers took to the concourse selling 50/50 tickets to fans. This incredible opportunity, made possible by the Boston Bruins Foundation, raised a grand total of $28,040 which was split between FRAXA and one lucky winner!
Read more

FX-Learn Clinical Trial for Children with Fragile X

Thirteen centers across the US enrolled children with Fragile X in a large-scale clinical trial of Novartis AFQ056. Dr. Elizabeth Berry-Kravis and colleagues aim to show that this targeted treatment — an mGluR5 blocker for Fragile X which failed in previous adult human trials — can be better evaluated by studying effects on learning in young children.
Read more

Over $20,000 Raised For Fragile X Research at Callum Cup V

After a one year hiatus, due the COVID-19 pandemic, the Callum Cup made a triumphant return last month. This annual intra-club charity match is the marquee event of the Millburn FC soccer calendar. The game being played in honor of Callum Murphy, the son of Andrew Murphy, one of the club’s goalkeepers.
Read more